The Chinese drug administration approved China Resources Double-Crane Pharmaceutical's (SHA:600062) supplementary application to increase the specifications of sugammadex sodium injection, according to a Shanghai Stock Exchange filing on Wednesday.
The specification of the drug will be raised to 5 milliliters:500 milligrams.
The drug is used for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults and for the reversal of rocuronium-induced blockade in children and adolescents, the pharmaceutical company said.
A new drug approval number that will be valid for 12 months will be issued.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。